尿路细菌对磷霉素的敏感性。
Susceptibility of urinary tract bacteria to fosfomycin.
作者信息
Maraki Sofia, Samonis George, Rafailidis Petros I, Vouloumanou Evridiki K, Mavromanolakis Emmanuel, Falagas Matthew E
机构信息
Department of Clinical Microbiology, University Hospital of Heraklion, Heraklion, Crete, Greece.
出版信息
Antimicrob Agents Chemother. 2009 Oct;53(10):4508-10. doi: 10.1128/AAC.00721-09. Epub 2009 Aug 17.
Abstract
We evaluated the in vitro activity of fosfomycin against urinary isolates in a region in Greece that exhibits considerable antimicrobial resistance by evaluating retrospectively relevant susceptibility data retrieved from the microbiological library of the University Hospital of Heraklion, Crete, Greece. We examined 578 urinary isolates. In total, 516 (89.2%) were susceptible to fosfomycin; 415 isolates were gram negative, and 101 isolates were gram positive. Fosfomycin appears to exhibit good levels of in vitro activity against the examined urinary isolates.
摘要
我们通过回顾性评估从希腊克里特岛伊拉克利翁大学医院微生物库中获取的相关药敏数据，来评估磷霉素对希腊某一地区尿液分离株的体外活性，该地区显示出相当程度的抗菌药物耐药性。我们检查了578株尿液分离株。总体而言，516株（89.2%）对磷霉素敏感；415株分离株为革兰氏阴性菌，101株分离株为革兰氏阳性菌。磷霉素似乎对所检测的尿液分离株表现出良好的体外活性水平。
相似文献
1
Susceptibility of urinary tract bacteria to fosfomycin.
Antimicrob Agents Chemother. 2009 Oct;53(10):4508-10. doi: 10.1128/AAC.00721-09. Epub 2009 Aug 17.
2
Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.
Future Microbiol. 2010 Jun;5(6):961-70. doi: 10.2217/fmb.10.47.
3
Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin.
Int J Antimicrob Agents. 2010 May;35(5):497-9. doi: 10.1016/j.ijantimicag.2010.01.010. Epub 2010 Mar 11.
4
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Int J Antimicrob Agents. 2010 Mar;35(3):240-3. doi: 10.1016/j.ijantimicag.2009.10.019.
5
In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
J Coll Physicians Surg Pak. 2014 Dec;24(12):914-7.
6
The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
BMC Urol. 2017 Apr 26;17(1):33. doi: 10.1186/s12894-017-0222-6.
7
Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Int J Infect Dis. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3.
8
9
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31.
10
Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
Int Urol Nephrol. 2017 Sep;49(9):1637-1643. doi: 10.1007/s11255-017-1627-6. Epub 2017 Jun 14.
引用本文的文献
1
Guidelines for Antibiotics Prescription in Critically Ill Patients.
Indian J Crit Care Med. 2024 Aug;28(Suppl 2):S104-S216. doi: 10.5005/jp-journals-10071-24677. Epub 2024 Aug 10.
2
The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy.
Antibiotics (Basel). 2023 May 27;12(6):971. doi: 10.3390/antibiotics12060971.
3
A Cost-Effectiveness Analysis of Fosfomycin: A Single-Dose Antibiotic Therapy for Treatment of Uncomplicated Urinary Tract Infection.
Health Serv Insights. 2022 Oct 10;15:11786329221126340. doi: 10.1177/11786329221126340. eCollection 2022.
4
Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.
Transpl Infect Dis. 2022 Aug;24(4):e13881. doi: 10.1111/tid.13881. Epub 2022 Jun 28.
5
A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients.
Indian J Crit Care Med. 2021 Sep;25(9):1055-1058. doi: 10.5005/jp-journals-10071-23958.
6
Antimicrobial Susceptibilities of Urinary Extended-spectrum β-lactamase to Fosfomycin.
Oman Med J. 2021 Nov 10;36(6):e314. doi: 10.5001/omj.2021.95. eCollection 2021 Nov.
7
Fosfomycin susceptibility of uropathogens at Charlotte Maxeke Johannesburg Academic Hospital.
S Afr J Infect Dis. 2020 Oct 26;35(1):173. doi: 10.4102/sajid.v35i1.173. eCollection 2020.
8
Fosfowash: Early proof of concept study investigating intravesical fosfomycin for recurrent urinary tract infections.
Can Urol Assoc J. 2021 Dec;15(12):423-424. doi: 10.5489/cuaj.7365.
9
Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients - a tertiary care centre experience.
Access Microbiol. 2020 Sep 3;2(10):acmi000163. doi: 10.1099/acmi.0.000163. eCollection 2020.
10
fosA3 overexpression with transporter mutations mediates high-level of fosfomycin resistance and silence of fosA3 in fosfomycin-susceptible Klebsiella pneumoniae producing carbapenemase clinical isolates.
PLoS One. 2020 Aug 28;15(8):e0237474. doi: 10.1371/journal.pone.0237474. eCollection 2020.
本文引用的文献
1
BSAC standardized disc susceptibility testing method (version 8).
J Antimicrob Chemother. 2009 Sep;64(3):454-89. doi: 10.1093/jac/dkp244. Epub 2009 Jul 8.
2
Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies.
Expert Opin Investig Drugs. 2009 Jul;18(7):921-44. doi: 10.1517/13543780902967624.
3
Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
Int J Antimicrob Agents. 2009 Aug;34(2):111-20. doi: 10.1016/j.ijantimicag.2009.03.009. Epub 2009 Apr 28.
4
[In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
Rev Esp Quimioter. 2009 Mar;22(1):25-9.
5
Addressing the challenge of extended-spectrum beta-lactamases.
Curr Opin Investig Drugs. 2009 Feb;10(2):172-80.
6
Antimicrobial resistance among uropathogens responsible for community-acquired urinary tract infections in an Italian community.
J Chemother. 2008 Dec;20(6):721-7. doi: 10.1179/joc.2008.20.6.721.
7
Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials.
Curr Med Res Opin. 2008 Dec;24(12):3423-34. doi: 10.1185/03007990802550679.
8
Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials.
Clin Ther. 2008 Oct;30(10):1859-68. doi: 10.1016/j.clinthera.2008.10.007.
9
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
Am J Med. 2008 Oct;121(10):876-84. doi: 10.1016/j.amjmed.2008.04.039.
10
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Arch Intern Med. 2008 Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897.
Zotero 插件